Helping your most specialized populations – an Xcenda analysis
Duchenne muscular dystrophy (DMD) is a devastating, muscle-wasting disease affecting only a small number of mostly adolescent males. However, discussions on evidentiary requirements, pricing, and access of pharmaceuticals are making international headlines. While there is no cure for DMD, a few treatments have reached advanced clinical development. Eteplirsen, ataluren, and deflazacort have garnered extensive media coverage related to appraisal and market access. Join our experts as they examine ways to sustain investment to ensure affordability for all stakeholders including patients, prescribers, payers, and society.